Pharm.D

Preferably Pharm.D, M.Pharm with Experience in Coordinating and conducting clinical trials. Clinical Research project A Phase II, Multi-center, Singlearm, Open-label Study to Assess the Efficacy and Safety of Tenalisib, a PI3K 5/y and SIK3 Inhibitor, in patients with Metastatic Triple Negative Breast Cancer.

Coordinate in screening, Audio-Video consenting, enrolment, periodic study visits and close out visit. Ensure that rights and well-being of a research participant is protected throughout the duration of the study.

Strong years of experience in pharmaceuticals, healthcare industry, specifically within innovative pharma. Strong years experience in Competitive Intelligence delivering insights on pipeline products excluding generics and biosimilars, targeted mechanisms of action, modalities, technology platforms and clinical trials activities.

BPharm, MPharm ; Malabar Cancer Centre, Thalassery, MCC is an autonomous institution under Health and Family Welfare Department, Government

Doctoral degree in Science, Engineering, Technology, Pharma from a recognized University or equivalent. Experience of working with national, international testing & certification laboratories, organizations.

MSc, PhD, PharmD, or MD. experience in medical communications. Medical writing experience. Demonstrate a command of assigned therapeutic areas and expertise with assigned products.

B.Pharm with experience in relevant field or M.Pharm experience in relevant field Or Pharm.D with experience in relevant field

A Prospective, Multicenter, Single-arm, Open-label, Phase IV, Post authorization Interventional Study to Assess the Safety and Efficacy of Asciminib in Indian Patients with Ph+ CML-CP without T315I Mutation, Previously Treated with two or more Tyrosine Kinase Inhibitors and Ph+ CML-CP with T315I Mutation

Evaluation of anti-inflammatory and immunomodulatory therapies using in vivo chronic inflammatory and autoimmune animal models such as psoriasis, colitis, and arthritis. Clinical and translational pharmacology focusing on patient-centric drug safety, pharmacovigilance, and outcome-based clinical investigations.